Uni-Bio Science Group (UNBSF) Fair Value & Analysis
Healthcare · US · Market cap $23.9M
Uni-Bio Science Group
UNBSF · US
Fair value as of: Jun 26, 2026
From 24 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0038 to $0.0040 (+5.1%) since Jun 25, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0036 – $0.0040 · fair‑value band $0.0039 – $0.0040 · the $0.0040 price screens above the $0.0040 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Uni-Bio Science Group (UNBSF) currently trades at $0.0040, while our model-based Fair Value estimate is $0.0040 — implying the stock looks roughly 0.2% overvalued today. We read business quality at 64/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, Uni-Bio Science Group generated revenue of $586M at a net margin of 15.9%. Revenue declined 1.2% year over year. It earns a return on equity of 25.3%. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People's Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage, and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; and Boshutai, for treating osteoporosis and bone pain. It also offers medical aesthetics. Uni-Bio Science Group Limited was incorporated in 2001 and is headquartered in Sha Tin, Hong Kong.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Uni-Bio Science Group reported revenue of $586M in FY2025 versus $353M in FY2021, a compound +13.5%/yr. Reported net income was $93.3M in FY2025.
Is UNBSF fairly valued? → Check now
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Uni-Bio Science Group (UNBSF) undervalued?
What is the fair value of UNBSF?
What is the quality score of UNBSF?
What is the revenue of Uni-Bio Science Group (UNBSF)?
What is the net profit margin of UNBSF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.